• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BLUE

BLUE

bluebird bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD4.97

+0.00 (+0.00%)

Company Profile

CEO

Andrew Obenshain

IPO Date

2013-06-19

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.97

Prev. Close

$4.97

Day Low

$4.97

Day High

$4.97

52W Low

$3.20

52W High

$28.60

Market Cap

$0.05B

Volume

1.25M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

16.7%

Avg Negative

39.3%

Avg Neutral

44.0%

News Feed

bluebird bio - The Good, The Bad And The Ugly

Seeking Alpha·8/13/2021·↓ negative

bluebird bio: Throwing My Thesis In The Can And Starting Over From Scratch

Seeking Alpha·8/11/2021·↑ positive

bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

Zacks Investment Research·8/9/2021·↓ negative

SVB Leerink Says 'We Were Wrong,' Slashes Bluebird Bio Price Target

Benzinga·8/9/2021·↓ negative

Why Bluebird Bio Stock Is Crashing Today

The Motley Fool·8/9/2021·↓ negative

Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/9/2021·↓ negative

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

Recap: bluebird bio Q2 Earnings

Benzinga·8/9/2021·↓ negative

Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

The Motley Fool·8/3/2021·↑ positive

bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

Business Wire·7/21/2021·↑ positive